Hold LIN with disciplined triggers; await breakout or washout signals before adjusting exposure
Maintain the trader's existing framework with discipline. The 8/28 OW failure demonstrated that tier increases without binary catalysts produce "Hold in disguise" with negative alpha, while the 9/1 UW reflection showed rangebound defensive trims produce only -0.3% alpha while sacrificing re-entry optionality. Neither aggressive nor conservative positioning is warranted; the well-calibrated plan with defined triggers at $503.50 breakout or $475-480 washout, stop at $473, and 15-20% trim only if outsized should be held. Q3 earnings in late October is the next binary fundamental catalyst; until then, hold the line.
| Position | Action |
|---|---|
| Position becomes outsized relative to portfolio parameters | Trim 15-20% of position |
| Breakout above $503.50 with volume >1.7M | Upgrade to Overweight, target $548 |
| Flush to $475-480 with volume >2M and RSI <35 | Upgrade to Overweight |
Linde is a high-quality compounder with expanding margins, accelerating buybacks, and a duopoly market position that makes it a buy-the-dip opportunity at current levels with asymmetric 4:1 upside/downside risk/reward.
| Indicator | Value | Signal |
|---|---|---|
| Close | 487.45 | neutral |
| 10 EMA | 486.88 | neutral |
| 50 SMA | 503.53 | bearish |
| 200 SMA | 477.88 | bullish |
| Bollinger Upper Band | 496.21 | neutral |
| Bollinger Middle Band (20 SMA) | 485.71 | neutral |
| Bollinger Lower Band | 475.21 | neutral |
| RSI (14) | 46.67 | neutral |
| MACD Line | -3.68 | bearish |
| MACD Signal | -5.35 | bearish |
| MACD Histogram |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price drops to $475-480 with volume > 2M and RSI < 35
Then: Upgrade to Overweight
↩ rebuts: “Bear view that rising capex is wasteful empire-building”
EV: +12-15% (to 52-week high at $548) · concedes: FCF has plateaued at ~$5B because capex is rising (but by design for future growth); D/E ratio of 73% is highest in years (but net debt/EBITDA at 1.6x is the right metric); Forward P/E of 25x is above market multiple (but PEG ~1.0 justified for quality compounder); One trailing-12-month period of underperforming the Dow (but this is noise, not signal)
Linde is a great business at the wrong price — trading at a 31.5x P/E with flat revenue, 76% higher net debt than three years ago, a $6.1B hydrogen capex bet dependent on policy support, and a goodwill overhang representing 46% of total assets — creating a risk/reward ratio of approximately 1:3 to 1:7 against current levels.
EV: -$420 to $450 fair value (bear case); $380-$400 downside scenario; only ~3.3% upside to 50 SMA ($503) vs 8-22% downside · concedes: Linde is a great business with genuine engineering capabilities and a real duopoly moat; The 200 SMA at $477.88 provides technical support in the near term; The buyback program is mechanically sound and will continue to provide some floor; Q3 earnings (late October) could provide upside catalysts if hydrogen offtake announcements materialize
→ vs conservative: Revenue 'stagnation' narrative is backwards—flat topline is pricing discipline and capital efficiency, not a weakness; 780 bps margin expansion and 21% EPS CAGR prove the business is one of most efficient capital allocation stories in American industry
→ vs conservative: CapEx concern is 'weakest argument'—$6.1B CIP doubled is a forward earnings pipeline, not a drag; incremental CIP of over $3B in last two years alone will convert at 28% operating margins
→ vs conservative: 89% no-cut probability creates multiple compression risk is 'backwards'—no cuts means no growth scare, no recession, stable industrial demand; cuts would signal economic weakness hurting end markets more than helping multiple
→ vs neutral: Price below 50 SMA at 503.50 is not overhead resistance—RSI recovered to 47 without overbought, MACD histogram positive and expanding, ATR compressed, price above rising 200 SMA at 477.88; '50 SMA is a magnet that's going to get reclaimed'
→ vs neutral: Volume at 1.15M vs 1.7–2.3M average is healthy absorption, not distribution—declining volume during consolidation signals sellers exhausted; remaining holders are conviction holders
→ vs neutral: Valuation at 25x forward is not 'heroic' or 'hard to justify' when backed by PEG under 1.0, 0.73 beta, 18% ROE, 780 bps margin expansion already delivered, and $6.1B CIP pipeline—'that's a multiple catalyst, not a multiple risk'
→ vs neutral: Caution-optimizing HOLD at 25x forward with improving momentum, recovering RSI, expanding MACD, rising 200 SMA, no recession risk, constructive macro, and no sell-side disagreement is 'paralysis, not risk management'; 'optimizing for comfort of inaction while missing asymmetric reward'
| +1.67 |
| bullish |
| ATR (14) | 8.71 | neutral |
| VWMA (20) | 484.37 | bullish |
| Volume | 1,153,614 | neutral |
Support: 475.21 · 474.33 · 477.88 | Resistance: 496.21 · 503.53 · 515.95
LIN is in a late-stage correction/early-stage basing phase after a sharp July gap-down from 508.64 to 478.38. Price holds above the rising 200 SMA (477.88) but remains below the declining 50 SMA (503.53), creating a mixed trend environment. Momentum is recovering—RSI climbed from 30.16 to 46.67 and MACD histogram turned positive (+1.67)—but MACD line stays negative (-3.68). ATR has compressed 32% from 12.82 to 8.71, signaling consolidation. The stock is positioned for a potential breakout above 496.21 (Bollinger upper) or breakdown below 475.21 (Bollinger lower/200 SMA support zone).
Market Cap
$224.70 B
P/E (TTM)
31.5x
Forward P/E
24.9x
Price / Book
5.75x
PEG Ratio
1.89
Dividend Yield
1.31%
Beta
0.73
52-Week High
$548.20
52-Week Low
$387.78
50-Day MA
$503.57
200-Day MA
$479.59
Forward EPS
$19.56
Revenue (TTM)
$35.45 B
Gross Profit (TTM)
$17.14 B
EBITDA (TTM)
$13.82 B
Net Income (TTM)
$7.24 B
Gross Margin (TTM)
48.4%
Operating Margin (TTM)
28.1%
Net Margin (TTM)
20.4%
ROE (TTM)
18.4%
ROA (TTM)
7.2%
TTM EPS
$15.48
2025 Diluted EPS
$14.61
2024 Diluted EPS
$13.62
Total Assets (2025)
$86.82 B
Total Debt (2025)
$28.07 B
Net Debt (2025)
$21.93 B
Stockholders' Equity (2025)
$38.25 B
Cash (2025)
$5.06 B
D/E Ratio (2025)
73%
Current Ratio (2025)
0.88
Operating Cash Flow (2025)
$10.35 B
Free Cash Flow (2025)
$5.09 B
Capex (2025)
$5.26 B
Dividends Paid (2025)
$2.81 B
Buybacks (2025)
$4.60 B
Total Capital Returned (2025)
$7.41 B
Revenue CAGR 2022-2025
+0.6%
EBITDA CAGR 2022-2025
+9.6%
Net Income CAGR 2022-2025
+18.5%
EPS CAGR 2022-2025
+21.0%
Revenue (2025)
$33.99 B
Revenue (2024)
$33.01 B
Revenue (2023)
$32.85 B
Revenue (2022)
$33.36 B
Net Income (2025)
$6.90 B
Net Income (2024)
$6.57 B
Net Income (2023)
$6.20 B
Net Income (2022)
$4.15 B
Net Debt / EBITDA
~1.7x
Capex / Sales (2025)
15.5%
FCF per Share (2025)
$10.78
Dividend per Share (2025)
~$6.00
Diluted Share Count (2025)
472M
Strengths
Concerns
Linde plc is the world's largest industrial gases and engineering company with a market cap of ~$224.7B and TTM revenue of ~$35.4B, formed through the 2018 merger of Praxair and Linde AG. Despite flat revenue over the past four years (~33B range), the company has achieved remarkable profitability expansion — operating margin expanded from 19.4% (2022) to 27.2% (2025), driven by post-merger cost synergies, Linde 2.0 productivity programs, and price/cost spread recovery. EPS grew at a 21% CAGR powered by both margin expansion and aggressive share buybacks (diluted share count reduced by 6%+ in 4 years). The company operates three geographic segments (Americas, EMEA, APAC) plus an Engineering division, serving heavy industrial, healthcare, electronics, and energy customers through long-term take-or-pay contracts and merchant/bulk sales. A stepped-up capex program ($5.3B in 2025, up 66% from 2022) is funding construction in progress that has nearly doubled to $6.1B, targeting clean hydrogen, blue/green ammonia, and large-scale ASU projects expected to ramp during 2026–2028. Free cash flow has plateaued at ~$5B as capex rises faster than operating cash flow, but the company funds extraordinary capital returns of ~$7.4B annually (dividends + buybacks) through deliberate balance sheet expansion. The stock trades near the high end of its 52-week range with a forward P/E of ~25x on ~26% implied EPS growth, with the principal risk being FCF dilution from elevated capex and rising leverage (D/E at 73%).